Ukraine can join India, Israel, and Thailand and become another major platform for the rapidly growing industry of clinical trials of new drugs, James Peyer, managing partner of the U.S. biotechnology company Apollo Ventures, has said. “Clinical trials can be carried out (in Ukraine) with the same level of professionalism, with the same level of effectiveness as in the United States and Europe but without their high costs,” he said at the Ukraine House Davos health panel.
As reported earlier, bill No. 4074 on ensuring public access to the results of preclinical study and clinical trials of medicines was passed into law by the Ukrainian parliament in September 2018.
At present, about 200 clinical drug trials are underway in Ukraine. At the same time, in the past two years, the trend toward a decrease in the number of clinical trials has subsided.
